TORONTO– This week, the Ontario Bioscience Innovation Organization (OBIO), a membership-based not-for-profit organization, is set to bring investors from around the world to its annual OBIO Investment Summit (OIS) and Early Technology Showcase (ETS), which showcases Canada’s leading innovations in health sciences, including biotech and medtech. According to OBIO’s analysis, the registered investors have approximately US$52 billion combined in unallocated and available funds to invest during the summit.
As part of its annual OBIO Investment Summit which takes place virtually starting February 9 to Friday, February 11, 2022, over 50 emerging Canadian companies will be in attendance, looking to bring their breakthrough innovations to market as part of Canada’s thriving health sciences technology industry.
“OBIO is welcoming over 100 global investors to their 2022 annual Investment Summit who will have the unique opportunity to access the best Canadian innovations in this sector,” says Dr. Maura Campbell, CEO of OBIO. “The summit has built on its strengths each year since 2018, and to date 101 companies have gone on to successfully raise over $1 billion in investment to boost Canada’s economy and its health sciences industry.”
The summit showcases investable companies, including the Early Technology Showcase, which this year, highlights 10 of Canada’s leading health research institutions presenting their latest breakthrough technologies, from mental health and cancer detection to AI and stem cell therapies. Together, the OIS and ETS bring together global investors, high potential Canadian companies, and top Canadian research institutions with the goal of bringing venture capital investment to Canada.
“The OBIO Investment Summit is a great venue for a preselected group of Canadian life sciences companies to showcase their technologies and connect to a diverse group of global investors and potential partners,” says Jacki Jenuth, Partner at Lumira Ventures. “We look forward each year to connecting with entrepreneurs at the Summit, learning of the opportunity for their business and being able to share some of our experience and insight from 20+ years of building great life sciences companies.”
